BPDCN treatment and management CD123-targeting agents the Video Journal of Hematology and Hematological Oncology podcast covers
Video Journal of Hematology and Hematological Oncology shared on their LinkedIn:
”NEW podcast episode: BPDCN treatment and management: CD123-targeting agents, CNS involvement and approaching pediatric/AYA patients.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoiddendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial for improving outcomes.
In this week’s episode, you’ll hear a discussion on the treatment and monitoring of BPDCN. The experts highlight the role of CD123-targeting agents, including tagraxofusp, the involvement of the central nervous system (CNS), and share strategies for treating adolescents and young adults (AYAs) with this aggressive disease.
With leading experts:
- Naveen Pemmaraju, The University of Texas MD Anderson Cancer Center.
- Marina Konopleva, Albert Einstein College of Medicine.
- Emanuele Angelucci, Armando Businco Oncology Hospital.
Use the time codes to skip to your favourite part of each episode!
The VJHemOnc Podcast covers latest news and trial updates in the hematology and hematological oncology space.
SUBSCRIBE so you don’t miss any future episodes.”
Source: Video Journal of Hematology and Hematological Oncology/LinkedIn